UBS upgrades argenx (ARGX) to Buy from Neutral and raises its price target to $1,400
UBS upgrades argenx (ARGX) to Buy from Neutral and raises its price target to $1,400 from $960, citing Vyvgart’s potential to become a $20B drug and broader platform.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.